Nuvaring (Ethinylestradiol, Etonogestrel)

The ring releases ethinylestradiol and etonogestrel, which bind to estrogen and progesterone receptors. This suppresses the hypothalamic‑pituitary‑gonadal axis, preventing the luteinizing hormone surge and ovulation, while also thickening cervical mucus and altering the endometrium to reduce the chance of implantation.

The dosing schedule for NuvaRing is determined by the prescribing healthcare professional. Typically, a single ring is inserted vaginally and left in place for three weeks, then removed for a one‑week ring‑free interval, after which a new ring is inserted.

NuvaRing is contraindicated in pregnancy (Category X) and should not be started or continued if a woman becomes pregnant. It is generally not recommended during breastfeeding; women should discuss alternative contraception with their healthcare provider.

To order NuvaRing, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

NuvaRing offers continuous hormone delivery via a vaginal device, which can improve cycle control and reduce daily pill‑taking adherence issues. Oral combined contraceptives require daily ingestion, whereas the ring is changed only once a month, providing comparable efficacy with a different administration route.

Store NuvaRing at room temperature, preferably below 25 °C, in its original packaging. Keep it away from moisture, direct sunlight and extreme temperatures to maintain the integrity of the hormone release system.

A healthcare professional or the user inserts the flexible vaginal ring into the upper vagina, where it remains for three weeks. After three weeks, the ring is removed and discarded, and a new ring is inserted after a one‑week interval.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe allergic reactions, hepatic disorders, and hypertension. Women with a history of clotting disorders, liver disease, or certain cancers should avoid using NuvaRing.

NuvaRing should not be used by women who are pregnant, have a known or suspected breast cancer, have a history of thromboembolic disease, have uncontrolled hypertension, have severe liver disease, or who smoke heavily (more than 15 cigarettes per day) and are over 35 years old.